Detalhe da pesquisa
1.
Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States.
Clin Breast Cancer
; 7(8): 627-33, 2007 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-17592676
2.
Establishment and characterization of xenografts and cancer cell cultures derived from BRCA1 -/- epithelial ovarian cancers.
Eur J Cancer
; 42(10): 1475-83, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16759848
3.
Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.
J Turk Ger Gynecol Assoc
; 16(3): 137-44, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26401105
4.
Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment.
Am J Clin Oncol
; 34(3): 305-8, 2011 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20622643
5.
Clinical experience and critical evaluation of the role of sorafenib in renal cell carcinoma.
Open Access J Urol
; 3: 69-82, 2011 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-24198638
6.
PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.
Cancer Res
; 71(7): 2750-60, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21317224
7.
The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families.
Cancer Res
; 68(17): 7006-14, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18703817